BBOT

BRIDGEBIO ONCOLOGY THERAPEUT

BBOT·107924102·US·Common Stock·Healthcare - Biotechnology-Activist

BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) is held by 39 institutional investors as of Q1 2026. Largest holders: Alphabet Inc. ($25.3M), WELLINGTON MANAGEMENT GROUP LLP ($25.2M), CITADEL ADVISORS LLC ($22.6M). Net institutional sentiment: Bullish.

39
Holders
Avg rating(4 Elite)
$143.3M
Total Value
74% (41)
Fund Consensus
26 buying - 9 selling
BBOTSmart Money Verdict
View all
Held by 39 funds
4 elite
Who's Trading
ActivistBCBihua Chen22.3%Jul 6, 2026
InsiderBYBen YongTax 1K shApr 1, 2026
InsiderBPBeltran PedroTax 1K shApr 1, 2026
InsiderMUMehra UneekTax 524 shApr 1, 2026
ActivistT. Rowe Price Associates, Inc.T. Rowe Price Associates, Inc.1.1%Nov 14, 2025
ActivistCitadel Advisors LLCCitadel Advisors LLC3.2%Nov 14, 2025
ActivistADAdage Capital Management, L.P.1.9%Nov 13, 2025
ActivistBGBC Global Opportunities IX LP5.5%Sep 3, 2025
ActivistDMDeerfield Mgmt, L.P.3.1%Aug 18, 2025
ActivistBPBridgeBio Pharma LLC17.5%Aug 18, 2025
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Unchanged
2.8M$25.3M0.6%-27.46%
0
Decreased
2.8M(-3.0%)$25.2M0.0%-27.46%
0
Decreased
2.5M(-0.1%)$22.6M0.0%-27.46%
0
Increased
2.1M(+0.2%)$18.7M0.0%-27.54%
28
New
636,522$5.7M0.1%-14.58%
37
Increased
579,234(+3.1%)$5.2M0.0%-27.34%
28
New
538,441$4.8M0.0%-14.58%
37
Decreased
437,889(-45.5%)$3.9M0.0%-27.46%
0
Decreased
400,000(-71.4%)$3.6M0.0%-27.46%
0
New
320,874$2.9M0.0%-14.58%
36
Increased
290,806(+4.2%)$2.6M0.0%-27.02%
27
Increased
265,954(+10.2%)$2.4M0.0%-26.44%
29
New
254,329$2.3M0.0%-14.58%
36
New
249,161$2.2M0.0%-14.58%
36
Unchanged
240,300$2.2M0.0%-29.27%
0
Increased
226,278(+3.7%)$2M0.0%-28.12%
27
Increased
167,573(+77.0%)$1.5M0.0%-25.88%
39
New
110,000$984,5000.0%-14.58%
35
Unchanged
103,707$928,1780.0%-27.46%
0
Increased
102,258(+76.2%)$915,2090.0%-22.40%
38

Showing 1-20 of 41

1 / 3

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used